SCHEMBL12876201

SCHEMBL12876201

Cc1cc(CCc2cccnc2)cc(-c2csc(Cn3cc(C(=O)O)cn3)n2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 2/20 0.40
KMT2A Q03164 1/20 0.38
RAB9A P51151 4/20 0.38
NPC1 O15118 3/20 0.38
EIF4E P06730 2/20 0.38
ALOX15 P16050 1/20 0.38
PTAFR P25105 1/20 0.36
DNM1L O00429 1/20 0.36
DHODH Q02127 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 1/20 0.35
AKT1 P31749 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
WNT1 P04628 1/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
ERCC5 P28715 1/20 0.35
TP53 P04637 1/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875981 0.92 KLKB1 (0.41) KLKB1RAB9ANPC1DHODHSMN1; SMN2
SCHEMBL1198613 0.87 ALDH1A1 (0.42) KLKB1KMT2ARAB9ANPC1EIF4E
SCHEMBL12876300 0.87 KLKB1 (0.36) KLKB1KMT2ARAB9AEIF4EDHODH
SCHEMBL12876129 0.87 KMT2A (0.45) KLKB1KMT2ADHODH
SCHEMBL12876294 0.86 RAB9A (0.36) KLKB1KMT2ARAB9ANPC1EIF4E
SCHEMBL12876130 0.85 KMT2A (0.37) KLKB1KMT2ARAB9ANPC1ALOX15
SCHEMBL12875968 0.84 L3MBTL1 (0.41) KLKB1RAB9ANPC1DHODHSMN1; SMN2
SCHEMBL12876187 0.84 GRM5 (0.38) KLKB1KMT2ARAB9ANPC1ALOX15
SCHEMBL12876264 0.83 DHODH (0.34) KLKB1RAB9ADHODHAKT1ALDH1A1
SCHEMBL12875995 0.82 ALKBH1 (0.48) KLKB1KMT2AL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A KLKB1 3765/4885KMT2A 3197/4885RAB9A 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.